April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 03, 2025

Youth Vaping: Comparable to Traditional Smoking, Study

Findings suggest that nicotine intake is similar among adolescents who vape and adolescents who smoke, highlighting critical implications for addiction.

Conexiant

April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 27, 2025

Medical Oddities: Metabolism’s Secret Sugar-Burning Switch

Science served weird this week: sleepy seniors, sneaky genes, and memory-hacking babies.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant

March 20, 2025

FDA Youth E-Cigarette Ad Linked to Lower Initiation

E-cigarette initiation among U.S. youth was reduced following The Real Cost Youth E-cigarette Prevention Campaign.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant